CHRNA4

Across TCGA pan-cancer cohorts, CHRNA4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHRNA4 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CHRNA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHRNA4 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

BLCA, SKCM, and KICH are the cancer types where CHRNA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.173	0.687	<.001	24	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.237	.029	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHRNA4–BLCA (OS)

Open the BLCA breakdown →